Results 151 to 160 of about 115,427 (296)

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

open access: yesThe Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama   +12 more
wiley   +1 more source

[18F] PSMA PET‐CT and [18F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests

open access: yesThe Prostate, Volume 86, Issue 7, Page 800-804, May 15, 2026.
ABSTRACT Background To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...
M. A. Tárraga‐Honrubia   +5 more
wiley   +1 more source

In the Era of mpMRI and PSMA PET/CT: Does Digital Rectal Examination Still Matter?

open access: yesThe Prostate, Volume 86, Issue 7, Page 805-810, May 15, 2026.
ABSTRACT Background With the increasing integration of multiparametric MRI (mpMRI) and 68Ga‐PSMA PET/CT into the diagnostic and staging algorithms of prostate cancer (PCa), digital rectal examination (DRE)—a once foundational and cost‐effective physical examination—has gradually become marginalized in daily clinical practice.
Anil Eker   +10 more
wiley   +1 more source

Perineal Prostatectomy

open access: yesInternational Journal of Clinical Practice, 1973
openaire   +2 more sources

The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density

open access: yesBJU International, Volume 137, Issue 5, Page 805-812, May 2026.
Objective To assess prostate volume (PV) changes with age in symptomatic and asymptomatic men with and without clinically significant prostate cancer (csPCa). In symptomatic patients, we additionally analysed the effect of age and csPCa on PSA and PSA‐density (PSA‐D) and compared these to current National Institute for Health and Care Excellence (NICE)
Jill Rusbridge   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy